Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Thera licenses diabetes candidate to DiaKine
Under the terms of the agreement, Cell Therapeutics Inc (CTI) will receive license fees, together with milestone payments on the achievement of predetermined development goals, royalties on sales
Under the terms of the agreement, Cell Therapeutics Inc (CTI) will receive license fees, together with milestone payments on the achievement of predetermined development goals, royalties on sales
Study results have been published in the Archives of General Psychiatry, one of the JAMA/Archives journals. According to background information in the article, life expectancy in patients with
The compound, currently known as NRP104, is in phase III clinical development in the US. New River Pharmaceuticals expects the product to reach the market in the US
Adolor will begin the recruitment process to hire 30 surgeon-focused sales representatives to collaborate with GlaxoSmithKline sales representatives in a combined national effort to co-promote Arixtra (fondaparinux sodium).
Following the receipt of this license, Azilect (rasagiline), a product co-developed between Teva and Lundbeck, and a joint development of Teva and the Technion Israel institute of Technology,
The supplemental biologics license application (sBLA) was filed on July 1, 2004, and was granted priority review status. The expanded indication will make Bexxar an earlier option for
The multi-center, randomized, controlled, four-arm study evaluates two different oral daily schedules of BAL8557, versus a weekly oral dose regimen, in comparison to fluconazole over a standard 14
The shares tumble came after the company provided an update on its AGI-1067 clinical program for the treatment of atherosclerosis in patients with coronary artery disease. The drug
Sinovac Biotech Ltd, also known in China as Beijing Kexing Bioproducts, has sold more than 1 million doses of its hepatitis A vaccine, Healive, at a price of
The program will evaluate the effect of Ampligen in patients infected by HIV-1 (with or without co-infection by hepatitis C virus) and virological failure with a randomized pilot